Navigation Links
Hemostatic drug less effective than originally predicted
Date:11/15/2010

The use of recombinant activated factor 7 (rFVIIa) a drug used to treat bleeding in hemophiliacs in patients without hemophilia is not recommended because of the potential for adverse events, found a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100408.pdf.

Recombinant activated factor 7 is a hemostatic agent licensed for the treatment of bleeding in hemophilia patients. It is also used "off-label" for the prevention and treatment of bleeding in patients without hemophilia including patients undergoing surgery, liver transplants and other procedures.

The use of rFVIIa in people without hemophilia appears to be common. For example, out of more than 2700 cases in the Australian and New Zealand Hemostasis Registry that use rFVIIa, only 1% had a diagnosis of hemophilia.

This systematic review was conducted to analyze the effectiveness and risks of rFVIIa in patients without hemophilia and to assess the implications of these results for future research.

"Physicians must believe that 'off-label' use is effective and outweighs risks," write Dr. Yulia Lin, Sunnybrook Health Sciences Centre and coauthors. "However, randomized controlled trials (RCTs) evaluating rFVIIa have raised concerns about adverse effects, particularly thromboembolic events (blood clots)."

The review, which looked at 14 prophylactic use RCTs including 1137 patients and 12 therapeutic use RCTs with 2538 patients, found uncertainty about the benefits and harms of this therapy.

"Clinically significant benefits of rFVIIa as a more general hemostatic drug (outside of hemophilia) remain unproven," conclude the authors. "This systematic review has not shown a consistent benefit of off-label rFVIIa use in the therapeutic setting and (at best) only modest benefits in the prophylactic setting. Given the potential risks, it cannot be recommended and in most cases, its use should be restricted to a clinical trial."


'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Source:Eurekalert

Related medicine news :

1. Hemostatic powder stops bleeding ulcers: Doctor
2. New Malaria Drug Proves Effective in Study of African Children
3. 5-year results show keyhole bowel cancer surgery is safe and effective
4. New lymphoma therapy may be more effective with fewer side effects
5. Diverse surgeons initiative effectively increases underrepresented minorities in academic surgery
6. Gene Mutations May Blunt Plavixs Effectiveness, Study Finds
7. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
8. Parent-only treatment may be equally effective for children who are obese
9. Home Monitoring of Blood-Thinner Use Appears Effective
10. Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment
11. Proton therapy safe, effective for early-stage lung cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... ... provider in the United States, today announced its partnership with financial technology company, ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Engineers at the ... because it produces the same kind of electrical energy that the body uses. ... of moving electrons. This flow of electrons out of the battery is generated by ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to ... Department of Health Care Services, will facilitate the development of a hub and ...
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
(Date:7/24/2017)... Solana Beach, California (PRWEB) , ... July 24, ... ... and commercialization of autologous fat (adipose) transfer systems announces the issuance of United ... (the ‘324 patent) for its adipose filtration technology. The '398 and '324 ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... 24, 2017 IBM (NYSE: IBM ) has ... for Solid-State Arrays (SSA) for the fourth year in a ... to Gartner, "Vendors in the Leaders quadrant have the highest ... A vendor in the Leaders quadrant has the market share, ... acceptance of new technologies. These vendors demonstrate a clear understanding ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 ... spending on brand medicines, generics and the supply chain account for ... just half of this (7 percent)? Or that the ... venture capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
Breaking Medicine Technology: